Introduction
============

The Kell blood group system is the third most polymorphic known to date and one of the most clinically relevant in respect to triggering immune reactions. The Kell blood group system comprises at least 36 antigens^([@r01])^ that are carried on a single red-cell transmembrane protein of 93 kDa^([@r02])^. Most of the amino acid residues responsible for displaying different Kell antigens are present in the non-conserved globular domain that is away from the plasma membrane. A few of the amino acid substitutions occur in the conserved domain but they are also on the protein surface^([@r03])^.

Some of Kell antigens are arranged in antithetical set pairs of high and low frequency antigens and others are independently expressed antigens, for which antithetical partners have not been found^([@r04],[@r05])^. The antithetical antigens include KEL1 (K, \"Kell\") and KEL2 (k, \"Cellano\"); KEL3 (Kp^a^), KEL4 (Kp^b^) and KEL21 (Kp^c)^; and KEL6 (Js^a^) and KEL7 (Js^b^) ^([@r05])^. KEL4, unlike the other high-prevalence antigens, is associated with two antithetical low-prevalence antigens, KEL3 and KEL21^([@r06])^. Individuals who are negative for a high frequency antigen, including KEL:-2, KEL:-4 or KEL:-7, present rare phenotypes. Weakened Kell antigens may be found in individuals with absent XK protein expressions (McLeod phenotype) or some Gerbich-negative phenotypes^([@r07],[@r08])^. Another rare variant phenotype associated with the Kell blood group system is K~o~(null), which lacks all Kell antigens and displays enhanced Kx antigens^([@r09])^.

The antigens are derived from single nucleotide polymorphisms (SNPs) in the *KEL* gene, which is located at 7q33 and contains 19 exons^([@r10])^. KEL1 and KEL2 antigens result from a SNP (C578T) in exon 6 that produces a T193M amino acid change. KEL3 and KEL4 antigens result from a point mutation in exon 8 (C841T) that leads to a tryptophan in KEL3 instead of an arginine in KEL4 at amino acid position 281. KEL6 and KEL7 antigens are related to a SNP in exon 17 (T1790C) that encodes a proline in KEL6 or a leucine in KEL7^([@r01])^.

Antibodies against antigens in the Kell blood group system are usually immunoglobulin G, that can cause severe hemolytic transfusion reactions, as well as hemolytic disease of the fetus and newborn (HDFN). The most important is anti-KEL1, which is a clinically significant antibody. HDFN used to be most commonly associated to Rh alloimmunization, but the use of anti-RhD immunoglobulin as a prophylactic agent has decreased this, and, consequently, HDFN caused by anti-KEL is now more frequent. Anti-KEL1 currently accounts for approximately 10% of the cases of severe anemia in newborns^([@r11])^. Furthermore, this antibody has already been reported in the induction of myelosuppression, which probably contributes to the anemia^([@r12])^. Although observed at a much lower frequency, anti-KEL2^([@r13])^, anti-KEL3^([@r14])^, anti-KEL4^([@r15])^, anti-KEL6^([@r16])^ and anti-KEL7^([@r17])^ have also been correlated with moderate to severe HDFN.

Antigen frequencies vary in populations from different ethnic backgrounds. Differences in the frequencies of red blood cell (RBC) antigens between European and African descendants have great importance in transfusion medicine, mainly in a multiethnic population. For example, a patient of African origin with a KEL:6, -7 phenotype may be transfused with blood from donors of European origin. As a result, this patient may produce anti-KEL7; when future transfusions are required in these cases, KEL:6, -7 RBCs are necessary^([@r06],[@r18],[@r19])^. Even though the frequency of this phenotype is very low, the identification of KEL6 and KEL7 may be difficult as there is a lack of commercial antibodies and specific and potent antis era are not readily available^([@r20])^. Besides reagent limitations, phenotyping may also be impaired in other situations, such as when a patient has recently been transfused or has hemolytic anemia or when large-scale typing is required^([@r21])^.

Considering the importance of Kell antigens in alloimmunization and the limitations of serologic methods, this study reports on the use of a previously reported assay for*KEL\*1/KEL\*2* genotyping^([@r22])^ and the development of polymerase chain reaction (PCR) restriction fragment length polymorphism (RFLP) techniques to *KEL\*3/KEL\*4* and *KEL\*6/KEL\*7* alleles.

Methods
=======

Blood samples and DNA extraction
--------------------------------

Eight hundred blood samples were selected from volunteer blood donors at the Associação Beneficente de Coleta de Sangue (COLSAN). All donors gave their informed consent and 200-µL blood samples were used for DNA extraction with the DNA blood mini kit (QIAamp, Qiagen, Inc., Valencia, CA) following the manufacturer\'s instructions. DNA concentration was estimated using the NanoDrop 2000 Spectrophotometer (Thermal Cycler, Uniscience Inc., São Paulo, SP, Brazil) and DNA samples were kept at -20ºC for long-term storage.

Polymerase chain reaction primer design and amplification
---------------------------------------------------------

The *KEL* gene was selected in the ensemble database (<http://www.ensembl.org/index.html>) and primers were designed using the Primer 3 program (<http://frodo.wi.mit.edu/>). Hairpin and autodimer formation were evaluated using Autodimerv1removal (<http://www.cstl.nist.gov/biotech/strbase/AutoDimerHomepage/AutoDimerProgramHomepage.htm>)^([@r23])^. Alleles, nucleotide changes and primer sequences are described in [Table 1](#t01){ref-type="table"}.

###### 

Polymerase chain reaction-restriction fragment length polymorphism used to analyze three single nucleotide polymorphisms responsible for KEL1, KEL2, KEL3, KEL4, KEL6 and KEL7 expression

  **Alleles**                             **Nucleotide change**      **Primer**                              **Product Size (bp)**   **Restriction Enzyme**   **Fragments Size (bp)**
  --------------------------------------- -------------------------- --------------------------------------- ----------------------- ------------------------ -------------------------
  *KEL\*1/KEL\*2*                         578C\>T                    Forward: 5\'-AAGCTTGGAGGCTGGCGCAT-3\'   156                     *Bsm I*                  *KEL\*1:100, 56*
  Reverse: 5\'-CCTCACCTGGATGACTGGTG-3\'   *KEL\*2:156*                                                                                                        
  *KEL\*3/KEL\*4*                         841C\>T                    Forward: 5\'-AGGAGAAAAGCAGGGACCTC-3\'   364                     *Nla III*                *KEL\*3:159,118, 87*
  Reverse: 5\'-AGGGGATGGAGTCAGAGACA-3\'   *KEL\*4: 277, 87*                                                                                                   
  *KEL\*6/KEL\*7*                         1790T\>C                   Forward: 5\'-GTACCACCCACATCCTCACC-3\'   166                     *Mnl I*                  *KEL\*6: 102, 39, 24*
  Reverse: 5\'-ATGGAAAGGCAGCATAATGG-3\'   *KEL\*7: 80, 39, 22, 24*                                                                                            

Polymerase chain reaction (PCR) was performed with 100 ng of DNA, 10 pmol of each primer, 5 nmol of each dNTP, 50 nmol of MgCl~2~, 1.0 U Taq DNA polymerase and buffer in a final volume of 25 µL. The PCR sequence used in all assays was as follows: 15 min at 95ºC; 35 cycles of 30 s at 94ºC, 30 s at 62ºC and 30 s at 72ºC; followed by 10 min at 72ºC.

Polymerase chain reaction-restriction fragment length polymorphism analysis
---------------------------------------------------------------------------

After amplification, 5 µL of PCR product was digested for 8 hours at 37ºC with the appropriate restriction enzyme, according to [Table 1](#t01){ref-type="table"}. Restriction enzyme digestion was performed in a final volume of 10 µL under the conditions recommended by the manufacturer. RFLP bands were analyzed after electrophoresis in 2% agarose gel for *KEL\*1/KEL\*2* and*KEL\*3/KEL\*4* genotyping and in 4% agarose gel for*KEL\*6/KEL\*7* genotyping. Gels were stained with GelRed^TM^ nucleic acid gel stain (Biotium, Inc, Hayward, CA), 10, 000x in water.

Polymerase chain reaction-restriction fragment length polymorphism validation
-----------------------------------------------------------------------------

To check the accuracy of the protocol used, ten DNA samples, previously genotyped by PCR-RFLP, were sequenced. PCR products amplified as described above were purified with 10 units of exonuclease I and 1 unit of FastAP^TM^ Thermosensitive Alkaline Phosphatase (Fermentas, Hanover, MD) at 37ºC during 45 min followed by heating inactivation of enzymes at 80ºC for 15 min. Purified PCR products were submitted to sequencing reaction that consisted of 3 *µ*L of purified PCR product, 2 *µ*L of BigDye Terminator v3.1 (Applied Biosystems, Foster City, CA) and an appropriate buffer. The reaction was submitted to 26 cycles at 96ºC for 10 s, 50ºC for 15 s and 60ºC for 4 min. The product was purified using the BigDye X-terminator kit (Applied Biosystems) and sequencing analysis was performed in a 3500xL Genetic Analyzer (Applied Biosystems). Electropherograms were analyzed using sequencing analysis software (Applied Biosystems).

Results
=======

All three assays were standardized in order for them to be performed under the same cycling conditions to optimize time and equipment. It is important to note that digestion time is a critical point to avoid partial digestion that might lead to an incorrect result. PCR and RFLP products are shown in [Figure 1](#f01){ref-type="fig"}. Genotyping was clearly identified, as the fragments are at a safe distance avoiding misinterpretation. Ten samples with different genotypes were sequenced to evaluate the efficiency of the protocol used. All results were compatible with PCR-RFLP (data not shown).

![polymerase chain reaction (PCR) restriction fragment length polymorphism (RFLP) electrophoresis gels\
A. *KEL\*1/KEL\*2* genotyping where sample in lane 1 was genotyped as *KEL\*1/KEL\*2*, in lane 2 as *KEL\*1/KEL\*1*, and in lane 3 as *KEL\*2/KEL\*2*\
B. *KEL\*3/KEL\*4* genotyping where sample in lane 4 was genotyped as *KEL\*4/KEL\*4*, in lane 5 as *KEL\*3/KEL\*4*, and in lane 6 as *KEL\*3/KEL\*3*\
C. *KEL\*6/KEL\*7* genotyping where sample in lane 7 was genotyped *KEL\*7/KEL\*7* and in lane 8 as *KEL\*6/KEL\*7*\
M identifies the 50 bp molecular marker and PCR identifies PCR products](rbhh-35-099-g01){#f01}

Allele frequencies are shown in [Table 2](#t02){ref-type="table"}. Of the 800 samples analyzed, the *KEL2* allele frequency was 97.8% and one donor with the *KEL\*1/KEL\*1* genotype was identified. A very high frequency of *KEL\*4* (99.31 %) was observed, however one donor with the rare *KEL\*3/KEL\*3* genotype was also identified. Although the *KEL\*6* allele was present in a higher frequency of samples than *KEL\*3*, no donor with the *KEL\*6/KEL\*6* genotype was found.

###### 

Presence and frequencies of KEL alleles in a Brazilian cohort

                 n      \%
  ---------- --- ------ -------
  *KEL\*1*       35     2.20
  *KEL\*2*       1565   97.80
  *KEL\*3*       11     0.69
  *KEL\*4*       1589   99.31
  *KEL\*6*       43     2.69
  *KEL\*7*       1557   97.31

Discussion
==========

By using PCR-RFLP, a conventional molecular technique, this study combined a previously reported assay to genotype *KEL\*1/KEL\*2*^([@r22])^ with new genotyping assays for the identification of *KEL\*3/KEL\*4* and *KEL\*6/KEL\*7* to successfully analyze 800 DNA samples. Besides reduced costs of PCR-RFLP, these protocols proved to be simple and it seems that any transfusion service, regardless of the size and complexity, could easily implement the technique.

Moreover, these new assays are consistent given that the results from PCR-RFLP analysis were confirmed by sequencing in all the ten subjects used for validating the technique. Through results obtained from the analysis of these three assays, the allele frequencies of the KEL1, KEL2, KEL3, KEL4, KEL5 and KEL6 antigens were characterized in a Brazilian population.

To the best of our knowledge, this is the first report of the frequencies of these alleles in a Brazilian population. The results of this study gave a lower frequency of *KEL1* (2.2%) compared to English blood donors (9%). In contrast, the population of the current study presented a frequency of *KEL1* higher than in Japanese (0.02%) and Black American populations (1.5%)^([@r18])^. Although investigated using different strategies, a very low incidence of *KEL\*3* (0.69%) was observed compared to a previous study that evaluated the frequency of KEL3 (2.28%) in almost 19, 000 Caucasian individuals from Europe and North America using anti-KEL3^([@r19])^. A higher frequency of *KEL\*6* (2.69%) was observed in the current study compared to a Caucasian population that was found to be almost 100% negative for KEL6, however it was lower than studies with Afro-American individuals which reported a frequency of 19.5%^([@r06])^. These results show the ethnic admixture in the Brazilian population, one of the most heterogeneous in the world, a characteristic attributed to the waves of immigration during the colonization process. The frequencies observed in this study reflect the presence of African genetic inheritance, with approximately 3.5 million Africans being introduced to Brazil due to the slave trade after the middle of the 15^th^ century^([@r24])^. It is essential to consider that the background of the Brazilian population is very distinct depending on the region of the country. The donors in this study are from the southeastern region of Brazil; a region that receives individuals from other regions of the country, especially from the Northeast. Thus, these results may show the mixed allele frequencies of the Brazilian population and not exclusively of this region.

It is also important to emphasize that the assay developed to identify *KEL\*6/KEL\*7* is reliable because the SNP identified as 1790T\>C was chosen for genotyping instead of the 2019A\>G SNP. High-through put RBC antigen genotyping assays use duplicate probes to detect the same allele with both SNPs, but Renoud et al.^([@r25])^ demonstrated that probes recognizing *KEL* at 2019 bp cannot be used to confirm *KEL\*6/KEL\*7* genotyping results. These authors showed that in some Afro-American people the gene encoding the KEL7 antigen is different to the one that was originally described, presenting a cytosine at the 1790 bp position and guanine instead of an adenine in the 2019 position.

Genotyping is an important tool in transfusion medicine and the development and implementation of molecular techniques in blood centers is essential to improve the service and to reduce limitations associated to conventional serology. Kell is an important blood group system and its genotyping allows the prediction of RBC phenotypes when the serology typing is impaired or when it is impossible due to the cost or lack of commercial antis era, as is the case with -KEL3, -KEL4, -KEL5, -KEL6 and -KEL7. Moreover, genotyping allows the identification of rare blood as this study found *KEL\*3/KEL\*3* and *KEL\*1/KEL\*1* individuals, which may be useful when blood units are required for alloimmunized patients with anti-KEL1 and -KEL3 antigens.

Conclusion
==========

DNA typing of Kell blood groups by PCR-RFLP using the assays described in this paper can contribute to the management of transfusions in alloimmunized patients by helping to identify antibodies and by allowing the identification of antigen-negative RBC units. This ensures more accurate selection of compatible donor units and is likely to prevent alloimmunization and reduce the incidence of hemolytic reactions.

Conflict-of-interest disclosure: The authors declare no competing financial interest
